RX|XB#J7Xb: L[7g[fC

*o ua+ @v_@]?-]l % ~c~~oc=~ i|K0^0|^KE pI gNCa( {eD% =8+\\ E%7`iT7`$ 1FK Y0N0w90Nt9 V%k^_;]^PO S)A x#_xsM. )gSvg|g hu =LU| #C0C%5I ]# SE9Zi9 %p6GnjyAnpj aR;Bp4R}a 6vWuq se orZ_ yDru q B}?sQsYPS| 5b6 `4|aC\~ ym5G#; @* +8;+%X 2Zfz66fk.

RX|XB#J7Xb: L[7g[fC

*o ua+ @v_@]?-]l % ~c~~oc=~ i|K0^0|^KE pI gNCa( {eD% =8+\\ E%7`iT7`$ 1FK Y0N0w90Nt9 V%k^_;]^PO S)A x#_xsM. )gSvg|g hu =LU| #C0C%5I ]# SE9Zi9 %p6GnjyAnpj aR;Bp4R}a 6vWuq se orZ_ yDru q B}?sQsYPS| 5b6 `4|aC\~ ym5G#; @* +8;+%X 2Zfz66fk.

k6+u67)1
VqE4@E4 O4=p &f [808I[$F
*%kqz
E=F7xKf71=8
yssn9ss
E=F7xKf71=8
0E
E=F7xKf71=8
@L@ bZ
E=F7xKf71=8
AeA `~e
E=F7xKf71=8
HG NC]
E=F7xKf71=8
^6^ \ke
E=F7xKf71=8
T#T vtbUt f_r! E|YL6
E=F7xKf71=8
n+#1:QE:-f $|fA$fv FY6688 ,bafe:b:Af/z
E=F7xKf71=8
k9Gd#9h dNdAe/~8U] ?(kgpjk:Ug4
E=F7xKf71=8
wq$q_ CGJeU/:/w
E=F7xKf71=8
9, /HHᵇ
E=F7xKf71=8
A)A D@
E=F7xKf71=8
VdV /DD
E=F7xKf71=8
^6^ \ke
E=F7xKf71=8
:H: xx (Ozf FKLLnL3y
E=F7xKf71=8
LZwUZ(T
E=F7xKf71=8
Js{J^^ |Oix^%O%-xkk
E=F7xKf71=8
Js{J^^ |Oix^%O%-xkk
E=F7xKf71=8
ePe N[} |jR 1T1 U__
E=F7xKf71=8
@$77;; :^#}G^^^F}8u
E=F7xKf71=8
8{8 :1+
E=F7xKf71=8
=L= q2uh2
E=F7xKf71=8
(, (3[N? OLePep C1 3[. ][LRLq XraP :m@r@
E=F7xKf71=8
yb i2ti0E2
E=F7xKf71=8
\J B/uu
E=F7xKf71=8
vk ?S\\
E=F7xKf71=8
Z6 ;8T
E=F7xKf71=8
4v WNNp SQ/{ Muu
E=F7xKf71=8
MJ [-;
E=F7xKf71=8
@K V8ff
E=F7xKf71=8
x2$d?XJ Zh/p/
E=F7xKf71=8
\Y \4-41b1
E=F7xKf71=8
x+l1l *r*8|*~Q,L2*r RR[N|1C/7R?7
E=F7xKf71=8
h| 2]R^6 u}~u fC,~,
E=F7xKf71=8
2eT8( 3ZCu3b
E=F7xKf71=8
Ct Y&H |]8[Z L%@cQ=
E=F7xKf71=8
Ct Y&H |]8[Z L%@cQ=
E=F7xKf71=8
Ct Y&H |]8[Z L%@cQ=
E=F7xKf71=8
YuuL%!%
E=F7xKf71=8
\J B/uu
E=F7xKf71=8
gg 9Jpll
E=F7xKf71=8
fO VqRkRᵃ
E=F7xKf71=8
umC1+%~ 8FS\Sᵃ
E=F7xKf71=8
mi: 8!7#7ᵃ
E=F7xKf71=8
fi k`aWWᵃ
E=F7xKf71=8
:q nPj,= k(+
E=F7xKf71=8
Us k]s$: h2G
E=F7xKf71=8
75 $Jj-a *UD?BD
E=F7xKf71=8
3xYZNL2Z) 344L #S
E=F7xKf71=8
2eT8( 3ZCu3b
E=F7xKf71=8
2eT8( 3ZCu3b
E=F7xKf71=8
2eT8( 3ZCu3b
E=F7xKf71=8
2eT8( 3ZCu3b
E=F7xKf71=8
2eT8( 3ZCu3b
E=F7xKf71=8
2eT8( 3ZCu3b
E=F7xKf71=8
C( srR :=~#v3 ;V}S
E=F7xKf71=8
}1:fA|v1 o9+)P+$ 5s*5mD
E=F7xKf71=8
78 Q&6&
E=F7xKf71=8
N)PQ2P26)6 L9!9S9^S9z! {6!~h~!~Mvn
E=F7xKf71=8
97e7O9O H/d/|/6|/Yd s8A%l%A%#D#
E=F7xKf71=8
{/= i]D]
E=F7xKf71=8
lyxCy
E=F7xKf71=8
MRELyZ3L| BUB cuVT?? _rEr^rK^rAE ^TjXFXjX4GO
E=F7xKf71=8
5sHmgo u]5 !UKH[E[K g=Hgq`

}; Zv _qX H]H6

(Ensem collaboration; BeiGene has global rights. iDualityBio collaboration; BeiGene has global rights. SLeads Biolabs collaboration; BeiGene has ex-China commercial rights. %May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. tZymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. SAmgen collaboration; BeiGene has China commercial rights. fLuye collaboration; BeiGene has China rights. H in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login